National Institute for Clinical Excellence (NICE) Rejects Use of Johnson & Johnson (JNJ)'s Prostate Cancer Drug Zytiga  
2/2/2012 7:53:18 AM

A Johnson & Johnson prostate-cancer medicine discovered in England and developed with funds from U.K. charities is too expensive for the country’s National Health Service. The NHS shouldn’t pay for Zytiga because the drug’s benefits don’t justify the cost even after the manufacturer agreed to cut the price, the National Institute for Health and Clinical Excellence said in a statement today. The agency, known as NICE, advises the state-run medical system on which treatments it should pay for. J&J and the public have a chance to comment on the decision, which is preliminary, NICE said.